IngredientsMethyl arbutin — also written as methylarbutin and catalogued in chemical databases as 4-methoxyphenyl β-D-glucopyranoside — is a naturally occurring phenolic glycoside. Methylarbutin, systematically named 4-methoxyphenyl β-D-glucopyranoside, possesses a molecular structure characterized by a hydroquinone core glycosidically linked to a glucose moiety, with a methyl ether group on the phenolic ring. Its CAS Registry Number is 6032-32-2, as listed in chemical reference databases. The chemical structure of methyl arbutin has been documented in the National Library of Medicine / National Center for Biotechnology Information, with its biological source recorded as Arctostaphylos uva-ursi (L.) Spreng., family Ericaceae, classified among phenolic heterosides.
Methylarbutin is a glycoside of hydroquinone monomethyl ether (4-methoxyphenol or mequinol) and is a derivative of the well-known skin-lightening agent arbutin. It is thus structurally distinguished from arbutin (β-arbutin, CAS 497-76-7) by the addition of a methyl group on the phenolic oxygen — a substitution that confers different physicochemical and, to some extent, biological properties relative to the parent compound.
To understand methyl arbutin, its parent compound arbutin must be appreciated. Arbutin (also called β-arbutin) is a natural product occurring in the leaves of a variety of different plants, the bearberries of the Ericaceae and Saxifragaceae families being prominent examples. It is a β-glucoside derived from hydroquinone (HQ; 1,4-dihydroxybenzene). Arbutin is sometimes called β-arbutin to distinguish it from the diastereomeric form α-arbutin (α-configuration at the anomeric center), which is not a natural product. Syntheses of α-arbutin have been reported, and it has similar, but not identical, biological properties. Methyl arbutin is yet a third, naturally occurring analogue within the same chemical family.
The standard known form of arbutin, β-arbutin, has a molecular formula of C12H16O7 and a molecular weight of 272.25 g/mol. Methylarbutin (4-methoxyphenyl β-D-glucopyranoside), by contrast, carries an additional methyl group on the aglycone oxygen, giving it a distinct molecular formula and weight from β-arbutin.
Like its parent compound arbutin, methyl arbutin is a member of the hydroquinone glycoside class. β-Arbutin is soluble in water, presenting typically as a white powder that remains stable under standard storage conditions. It exhibits stability in both ethanol and water and demonstrates resistance to light exposure. When dissolved in water, β-arbutin may undergo hydrolysis, converting to hydroquinone, which can subsequently oxidize to benzoquinone. Similar hydrolytic susceptibility applies in principle to methyl arbutin, though the methyl ether substitution modulates its enzymatic degradation profile relative to arbutin. Arbutin undergoes decomposition into hydroquinone and p-benzoquinone when exposed to temperature stress, ultraviolet light, or dilution in an acidic environment, all of which can induce skin toxicity.
Methylarbutin is a naturally occurring compound found in various plant species, most notably in bearberry (Arctostaphylos uva-ursi). Arctostaphylos uva-ursi (bearberry) contains a steroid, sitosterol, and triterpenoids, such as amyrin, betulinic acid, lupeol, oleanolic acid, taraxenol, ursolic acid, and uvaol. The main constituent is a glucoside called arbutin. Other constituents are methylarbutin, ericolin, ursone, gallic acid, and ellagic acid.
Uva-ursi leaves also contain small amounts of free hydroquinone (<0.3%), another hydroquinone derivative — the glycoside methylarbutin (up to 4%) — and flavonoids such as hyperoside (0.8%–1.5%). The dried leaves contain hydroquinone derivatives, mainly arbutin and methyl arbutin, at concentrations ranging from 5% to 15%. Methyl arbutin thus co-occurs with arbutin in bearberry leaf at considerably lower concentrations than the dominant glycoside.
The leaves of Arctostaphylos uva-ursi contain arbutin, methyl arbutin together with arbutin galloyl derivatives (O-galloyl arbutin, 2-O-galloyl arbutin, 6-O-galloyl arbutin) (EMEA, 2012). Beyond bearberry, arbutin and its analogues — including methyl arbutin — are distributed broadly across the plant kingdom. Since its discovery, arbutin has been detected in approximately 50 other plant families. While the plants from the families Asteraceae, Ericaceae, Proteaceae, and Rosaceae are the main sources, at least 45 other plant families have been reported to produce this glycoside.
The primary natural source of β-arbutin is bearberry leaves (Arctostaphylos uva-ursi). It is also found in pears, wheat, coffee, and tea. Although β-arbutin is widely available in plants, its extraction is hindered by its low content, the complicated extraction process, and low purity of the extracted product.
Methyl arbutin is present in crude and standardized extracts of bearberry leaf (Uvae ursi folium), which is the primary herbal preparation form. The bearberry leaf (Uvae ursi folium) is highly valued and sought by pharmaceutical and cosmetic industries. Preparations derived from Arctostaphylos uva-ursi in which methylarbutin is a constituent include aqueous infusions (teas), film-coated tablet extracts, tinctures, dry extracts, and topical cosmetic formulations. Until recently, plant substances, especially Uvae ursi folium, have been the basic sources of arbutin. Nowadays, plant extracts are increasingly replaced by chemically and biotechnologically synthesized arbutin and its derivatives. In isolation, methyl arbutin (CAS 6032-32-2) is available as a research-grade chemical. Primary synthetic routes for methylarbutin (4-methoxyphenyl-β-D-glucopyranoside) include both chemical and enzymatic synthesis methodologies.
Methyl arbutin has no independent history of traditional use; it has been consumed as a constituent of bearberry leaf preparations alongside the dominant glycoside arbutin. The history of bearberry (Arctostaphylos uva-ursi) as a medicinal plant therefore forms the sole traditional context for methyl arbutin exposure.
The main natural source of arbutin, the bearberry (Arctostaphylos uva-ursi (L.) Spreng.), has been used for centuries to treat urinary tract infections and other renal diseases, and herbal formulations are still prepared today. Uva ursi has been used extensively in native cultures since the Middle Ages and is listed in the pharmacopoeias of many Western societies for the treatment of urinary conditions, primarily symptoms of urinary tract infection.
For many years, leaves of this plant have been used in traditional medicine as a diuretic, antimicrobial, and anti-inflammatory agent for various diseases of the urogenital tract.
According to the WHO Monographs on Selected Medicinal Plants (Volume 2, 2002), bearberry is described in pharmacopoeias and in traditional systems of medicine as a mild urinary antiseptic for moderate inflammatory conditions of the urinary tract and bladder, such as cystitis and urethritis. Uses described in folk medicine include use as a diuretic, to stimulate uterine contractions, and to treat diabetes, poor eyesight, renal or urinary calculi, rheumatism, and venereal disease, as well as topically for skin depigmentation.
Arbutin has been identified in traditional Chinese folk medicines as having, inter alia, anti-microbial, anti-oxidant, and anti-inflammatory properties useful in the treatment of different ailments including urinary diseases. Similarly, in traditional Japanese medicine, extracts containing arbutin have been applied topically to promote skin brightening and to address related conditions.
The bearberry plant's geographic distribution encompasses North America, Asia, and northern Europe. Uva ursi is found in North America, Asia, and northern Europe. Traditional use therefore spans Indigenous North American peoples, European herbalists dating to the medieval period, and Asian medicinal traditions.
The German Commission E monograph suggests half to three-quarters of a teaspoon (3 grams) of uva ursi steeped in about 5 ounces (150 ml) of boiling water and drunk as an infusion three to four times daily. For alcohol-based tinctures, 1 teaspoon (5 ml) three times per day can be used. Both aqueous infusions and alcoholic tinctures thus represent the principal traditional delivery formats for bearberry-derived phenolic glycosides, including methyl arbutin.
When methyl arbutin is encountered clinically or in dietary supplement use, it is invariably co-administered with the broader phytochemical matrix of bearberry leaf. The principal constituents relevant to the discussion of methyl arbutin's pharmacological context include:
The natural product arbutin is the β-D-glucopyranoside of hydroquinone (HQ; 1,4-dihydroxybenzene). It is a β-glucoside derived from hydroquinone. Methyl arbutin differs by a single methyl etherification at the para-hydroxyl position of the aglycone (hydroquinone), yielding the methyl ether of hydroquinone (4-methoxyphenol, also called mequinol) as the aglycone, rather than hydroquinone itself. This structural difference has pharmacological consequences: when methyl arbutin is hydrolyzed in the body, its aglycone is 4-methoxyphenol rather than hydroquinone, which is less cytotoxic than hydroquinone.
Tyrosinase is the key and rate-limiting enzyme responsible for the conversion of tyrosine into melanins by melanocytes in human skin. Inhibition of the enzymatic activity of tyrosinase by competitive inhibitors results in decreased or absent melanin synthesis by the melanocytes.
Methylarbutin, systematically named 4-methoxyphenyl β-D-glucopyranoside, possesses a molecular structure characterized by a hydroquinone core glycosidically linked to a glucose moiety, with a methyl ether group on the phenolic ring — a configuration that positions it, like arbutin, as a structural mimic of the tyrosinase substrates tyrosine and L-DOPA, enabling competitive binding at the enzyme's active site. Arbutin is a naturally occurring derivative of hydroquinone found in bearberry that is structurally homologous to tyrosinase and competitively inhibits melanosomal tyrosinase and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) polymerase activities.
A hypothetical mechanism for the inhibition of eumelanin synthesis by arbutin involves its tyrosinase (TYR) inhibitory and antioxidant activities. Arbutin inhibits the catalytic activity of TYR. It also scavenges reactive oxygen species (ROS) from various sources that can induce melanin synthesis, apoptosis, or tumorigenesis. It can activate the erythroid 2-associated factor 2 (Nrf2)-antioxidant responsive elements (ARE) pathway to enhance the antioxidant capacity of cells.
Arbutin (p-hydroxyphenyl-β-D-glucopyranoside), a well-known tyrosinase inhibitor which can be extracted from plants, has been widely used for the purpose of skin whitening. Regarding the molecular base mechanisms of arbutin, it was reported that arbutin inhibits not only the oxidation of L-DOPA but the hydroxylation of L-tyrosine.
The tyrosinase-inhibiting property applies specifically to methyl arbutin as well. As a derivative of the well-known skin-lightening agent arbutin, methylarbutin has garnered significant interest for its potential applications in the cosmetic and pharmaceutical industries, with a focus on its mechanism of action as a tyrosinase inhibitor and its role in modulating key signaling pathways.
The classical mechanism of antibacterial activity attributed to bearberry preparations, involving both arbutin and methyl arbutin, depends on hydrolysis in the urinary tract. The uroantiseptic properties of A. uva-ursi are primarily attributed to the phenolic glycosides arbutin and methylarbutin, or their metabolite hydroquinone. Additionally, polyphenols (tannins) are also thought to contribute to its antimicrobial effects.
The reputed antibacterial activity of bearberry is ascribed to the urinary metabolite hydroquinone, which is excreted in the form of inactive conjugates and needs an alkaline urine to be liberated. As the urine of people who consume a Western non-vegetarian diet is usually acidic, it is sometimes suggested that one should alkalinize the urine of bearberry users with sodium bicarbonate.
Arbutin, a major constituent of bearberry, is absorbed by the gastrointestinal tract in unchanged form, but is ultimately eliminated in the urine as hydroquinone conjugates that are hydrolyzed to hydroquinone in alkaline urine. An in vitro microbiological study revealed strong antibacterial properties in urine samples obtained from healthy volunteers after consumption of 800 mg of arbutin or bearberry containing an equivalent amount of arbutin. This effect was observed only with urine adjusted to a pH of 8, whereas urine at pH 6 was ineffective. It has been reported that this free hydroquinone exerts antiseptic and astringent effects.
The hydroxyl radical, as determined by an electron spin resonance-spin trapping technique, is generated by the addition of not only L-tyrosine but also L-DOPA to tyrosinase in a concentration-dependent manner. Arbutin can inhibit the hydroxyl radical generation in both reactions. It is presumed that arbutin could alleviate oxidative stress derived from the melanogenic pathway in the skin, in addition to its function as a whitening agent in cosmetics. This antioxidant activity is relevant to both the cutaneous and systemic effects attributed to the bearberry glycoside family.
Bearberry leaf extracts, in previous studies, showed antioxidant activity due to the presence of arbutin, hydroquinone, methylarbutin, hyperoside, and flavonoids. Methyl arbutin is thus considered to be one of several antioxidant constituents in the plant matrix, though its individual contribution relative to arbutin has not been isolated in human studies.
Arbutin has been identified in traditional Chinese folk medicines as having, inter alia, anti-microbial, anti-oxidant, and anti-inflammatory properties. Animal model data support an anti-inflammatory effect for arbutin. In an LPS-induced rat model of acute lung injury, arbutin (50 mg/kg) prevents increases in IL-1β, IL-6, and TNF-α levels in lung tissue and serum. Whether methyl arbutin independently shares these anti-inflammatory properties has not been verified in clinical research.
Background: The skin-lightening application of bearberry glycosides, including methyl arbutin, has received the most scientific attention, though the bulk of direct clinical evidence pertains to arbutin or α-arbutin rather than methylarbutin specifically.
It has been about 30 years since arbutin was studied in earnest for use as a hydroquinone alternative for skin lightening purposes. Today, arbutin is used worldwide for the treatment of skin ailments by way of depigmenting, meaning that arbutin is a component of many products in the cosmetics and healthcare industries.
Human/clinical evidence: In a clinical trial of 50 females (34 Caucasian lighter-skinned individuals and 16 non-Caucasian darker-skinned individuals) with solar lentigines, topical treatment of arbutin for 12 weeks resulted in a slight to significant reduction in overall skin lightness and improvement of solar lentigines. This trial assessed arbutin (β-arbutin), not methylarbutin in isolation, and represents one of the few randomized human clinical studies conducted. Combined therapy with arbutin and laser could give enhanced depigmenting efficacy.
Preclinical / cell-culture evidence: Arbutin both inhibits melanin production in B16 cells induced with alpha-MSH and decreases tyrosinase activity in a cell-free system. Arbutin inhibits human tyrosinase activity in crude tyrosinase solution isolated from human melanocytes (IC50s = 5.7 and 18.9 mM using L-tyrosine and L-DOPA as substrates, respectively) as well as in intact melanocytes (IC50 = 0.5 mM).
Evidence strength: For the class of arbutin glycosides (arbutin, α-arbutin), moderate clinical evidence supports topical skin-lightening efficacy. For methyl arbutin specifically, published human clinical trials are absent; evidence of tyrosinase inhibition and antimelanogenic activity remains primarily from in vitro and animal studies. Claims about methyl arbutin's depigmenting potency as an isolated ingredient cannot be independently verified from clinical data at the current time.
Background: The use of bearberry preparations — in which methyl arbutin co-occurs with arbutin — for symptomatic treatment of lower urinary tract infections has been documented since the Middle Ages and is formally recognized in major regulatory monographs.
Arctostaphylos uva-ursi and its leaf preparations are generally considered to have antibacterial activity and are traditionally used for treatment of lower urinary tract infections. Published literature provides information on antibacterial activity of bearberry leaf preparations together with several other activities. Publicly available is also information on arbutin and hydroquinone, which are the components generally considered to be responsible for the antibacterial activity of the extract.
In vitro microbiological evidence: Bearberry leaf provides arbutin, which is hydrolyzed in alkaline urine to hydroquinone, yielding minimum inhibitory concentration (MIC) values of 0.21 to 0.6 mg/mL against E. coli and S. saprophyticus.
Human clinical evidence: No human trials have been published confirming the effectiveness of uva ursi in people with urinary tract infections. One formally registered double-blind, randomized controlled comparative effectiveness trial — the REGATTA trial — has been designed to address this gap. Arctostaphylos uva-ursi (UU, bearberry extract arbutin) is a potential alternative treatment. The study aims at investigating whether an initial treatment with UU in women with UTI can reduce antibiotic use without significantly increasing the symptom burden or rate of complications. Women between 18 and 75 years with suspected UTI and at least two of the symptoms dysuria, urgency, frequency, or lower abdominal pain were assessed for eligibility. Participants received either a defined daily dose of 3 × 2 arbutin 105 mg for 5 days (intervention) or fosfomycin 3 g once (control).
Diuretic activity: Beyond its antimicrobial properties, in vivo studies have confirmed a diuretic effect, which is believed to be linked to its flavonoid content.
Evidence strength: Overall evidence for the urinary tract application of bearberry-derived glycosides (including methyl arbutin as a constituent) is weak to preliminary at the clinical level. In vitro antibacterial data are supportive, but rigorous human trial evidence is currently lacking or pending. Methyl arbutin as an isolated compound has not been the subject of dedicated urinary tract clinical research.
Among the positive effects of arbutin are its antioxidant properties, antimicrobial properties, and anti-inflammatory properties. Bearberry has also been proposed as a natural antioxidant additive due to the high contents of phenolic compounds in leaves. The antioxidant contributions of methyl arbutin within the bearberry phytochemical matrix are noted in the scientific literature, but methyl arbutin has not been studied in isolation for this application in human trials.
In addition to its skin whitening property, arbutin possesses other therapeutically relevant biological properties, including antioxidant, antimicrobial, and anti-inflammatory activities, as well as anticancer potential. Published outputs suggest that arbutin has potential anticancer properties against bladder, bone, brain, breast, cervix, colon, liver, prostate, and skin cancers, and a low level of acute or chronic toxicity. These findings are derived from preclinical (cell culture and animal) models. Bearberry leaf extracts, which in previous studies showed antioxidant activity due to the presence of arbutin, hydroquinone, methylarbutin, hyperoside, and flavonoids, have been investigated for activity against glioblastoma.
Evidence strength: Anticancer data for the arbutin family, including methyl arbutin, are exclusively preclinical (in vitro and rodent models). No human clinical trials examining methylarbutin or arbutin as anticancer treatments have been published.
The hepatoprotective mechanism of arbutin, a glycosylated hydroquinone, against cisplatin-induced hepatotoxicity has been investigated. Rats were orally administered arbutin (50 mg/kg or 100 mg/kg) for 14 consecutive days against hepatotoxicity induced by a single dose of cisplatin (10 mg/kg) on day 15. These are exclusively animal model findings and have not been replicated in human trials.
One study investigated arbutin, a natural polyphenol compound, enhanced dramatically myelin regeneration in LPC-induced demyelinated rat optic chiasm through suppression of oxidative stress. Again, this represents animal-model, not human, evidence.
Published dosage data pertain to preparations of Arctostaphylos uva-ursi (bearberry leaf) in which methyl arbutin is a co-constituent with arbutin, rather than to isolated methyl arbutin. No standardized or clinically studied dosage for methyl arbutin in isolation has been identified in the peer-reviewed literature.
The principal safety concern specific to the arbutin/methylarbutin family is their hydrolysis to hydroquinone in vivo. The most representative constituent of bearberry leaf is arbutin, which is rapidly absorbed in the small intestine and undergoes hepatic conjugation to form hydroquinone (HQ) conjugates. Because arbutin is broken down to yield free HQ and glucose, concerns regarding the safety of free HQ have raised questions about the safety of herbal preparations of bearberry leaves — it was primarily suspected to induce hepatotoxicity, nephrotoxicity, and other organ toxicity as well as genotoxicity.
A systematic safety review of the available clinical and epidemiological literature found: There appears to be no clinical data that associate hepatotoxicity with arbutin or free HQ from dietary or herbal product consumption. Several occupational epidemiological studies on workers exposed to hydroquinone via inhalation or dermal contact provided no evidence for systemic toxic effects, including hepatotoxicity, from long-term occupational exposure to HQ.
A daily dose equivalent to 420 mg anhydrous arbutin releases less than 11 µg/kg body weight of hydroquinone, which remains well below toxicological thresholds and supports its short-term use in acute cystitis.
Arbutin and deoxyArbutin are both effective hypopigmentation agents; however, they are glucoside derivatives of hydroquinone which may be degraded into hydroquinone under higher energy environments. Therefore, safety and toxicity are very important issues when considering the usage of these compounds. UVB-irradiated arbutin and deoxyArbutin have strong cytotoxicity for fibroblast cells. The results correlated with the produced hydroquinone. This finding is directly relevant to methyl arbutin in topical formulations, as UV exposure of the preparation can liberate cytotoxic aglycone.
Regulatory authorities have specified short-term use constraints. Regulatory guidance currently states it is not clear if extended use is safe, and patients are advised not to use it long-term. More evidence is needed to support use for UTIs.
Preparations of bearberry leaf should not be taken together with drugs that cause acidic urine, since this reduces the antibacterial action. High doses of vitamin C and cranberry juice will transiently acidify the urine in a minority of people. Considering that arbutin may convert preferentially to hydroquinone in alkaline urine, urinary acidifiers can theoretically inhibit this conversion. As the urine of people who consume a Western non-vegetarian diet is usually acidic, it is sometimes suggested that one should alkalinize the urine of bearberry users with sodium bicarbonate. However, as the dosage recommended for this purpose is usually high, this carries well-known risks such as a high sodium load and interference with the renal clearance of certain other drugs.
High tannins (co-present in bearberry leaf) may interfere with absorption of various nutrients, including iron.
While plant-based therapies are widely regarded as safe alternatives or adjuncts to conventional antibiotics for preventing recurrent UTIs, their long-term use, particularly in women with underlying conditions such as diabetes mellitus or chronic catheterization, warrants careful consideration.
Arbutin is a natural glycosylated hydroquinone of the bearberry plant, and it is safer and less cytotoxic compared with hydroquinone. Hydroquinone has numerous unfavorable effects with long-term application, including irritative dermatitis, melanocyte destruction, contact dermatitis, and ochronosis. Because methyl arbutin yields 4-methoxyphenol (mequinol) rather than hydroquinone upon hydrolysis, its cytotoxicity profile may differ further from arbutin's, though this has not been systematically characterized in standalone human safety studies.
Bearberry leaf preparations are recognized in multiple official pharmacopoeial and regulatory monographs. The EMA has published an assessment report on Arctostaphylos uva-ursi (L.) Spreng. folium as an herbal medicinal product. Methyl arbutin as an isolated ingredient does not have its own EMA, WHO, or USP monograph and is encountered primarily as a constituent of standardized bearberry leaf preparations.
According to EMEA (2012) monographs, arbutin-containing plant materials are used in the treatment of urinary tract infections.
Health conditions that Methyl arbutin may help support.
Body systems that Methyl arbutin may help support.
Go back